Table 1 FDA-approved anti-infective drugs versus MRSA treatment management

Vancomycin

Slow bacterial action (dose cell wall inhibition independent of concentration)

500 mg q6h or 1000 mg q12h per oral/1 μg/ml in IV

Inexpensive and 50 years of clinically prescribed drug

Nephrotoxicity, red man syndrome

Linezolid

Protein synthesis inhibition; Bacteriostatic (23 s RNA at 50S ribosomal subset)

IV or PO 600 mg q12h

100% bioavailable oral preparation, upright drug permeation into the lung and beside VRE

Thrombocytopenia and anemia lactic acidosis, serotonin syndrome occurs long term uses

Daptomycin Bactericidal

Bactericidal; membrane depolarization (ca++ dependent)

IV: cSSSI:4 mg/kg (total body weight) OD; S. aureus bacteremia, 8 to 10 mg/kg in endocarditis indications

Swiftly bactericidal active for MRSA blood flow infection and endocarditis

Cpk elevation, myopathy, neuropathy diseases, eosinophilic pneumonia

Tigecycline

Bacteriostatic, which means the inhibition of protein synthesis happens at the 30S ribosomal subunit

IV: 50 mg q12h

Active against VRE

GI complications such as nausea and vomiting

Telavancin

Cell Wall Inhibition and Membrane Depolarization; (dose concentration-dependent); bactericidal

IV: 10 mg/kg (total body weight) OD

Swiftly bactericidal beside MRSA, active alongside Strains of MRSA which are no longer susceptible to Vancomycin, linezolid, and daptomycin

Mild QT prolongation, nephrotoxicity, GI side effects

Ceftaroline

Cell Wall Inhibition (with Bactericidal Effects): Time-Dependent

IV:600 mg q12h

Bactericidal agents, moderately expensive

Diarrhea, nausea and skin rash